Europe Acute Respiratory Distress Syndrome (ARDS) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 MULTIVARIATE MODELLING 53
2.7 CAUSE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET END USER COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PESTEL ANALYSIS 65
4.2 PORTERS FIVE FORCES 66
5 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 67
5.1 REGULATION IN U.S.: 67
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA 68
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES 69
5.4 LABELING OF MODIFIED DEVICES 69
5.5 REGULATION IN EUROPE: 70
5.6 REGULATION IN INDIA: 71
5.7 REGULATION IN JAPAN: 72
6 REGIONAL SUMMARY 73
6.1 NORTH AMERICA REGION 73
6.2 EUROPE REGION 74
6.3 ASIA-PACIFIC 74
6.4 SOUTH AMERICA 75
6.5 MIDDLE EAST AND AFRICA 75
7 PIPELINE ANALYSIS 76
8 INSURANCE REIMBURSEMENT 78
8.1 CENTER FOR MEDICARE SERVICES (CMS)ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 78
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 79
8.3 ABBOTT CODING GUIDE FOR ECMO 79
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 80
8.5 CERN HEALTH INSURANCE SCHEME 80
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)  (MEDICARE & MEDICAID) 80
8.7 AMERICAN HOSPITAL ASSOCIATION 81
8.8 CONCLUSION 81
9 MARKET OVERVIEW 82
9.1 DRIVERS 84
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 84
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 84
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 85
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 85
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 86
9.2 RESTRAINTS 86
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 86
9.2.2 HIGH COST OF DEVICE AND TREATMENTS 87
9.2.3 LACK OF SKILLED WORKFORCE 87
9.3 OPPORTUNITIES 88
9.3.1 GROWING GERIATRIC POPULATION 88
9.3.2 RISING HEALTHCARE EXPENDITURE 89
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 89
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 90
9.4 CHALLENGES 91
9.4.1 STRINGENT RULES & REGULATIONS 91
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 91
10 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 93
10.1 PRICE IMPACT 93
10.2 IMPACT ON DEMAND 94
10.3 IMPACT ON SUPPLY CHAIN 95
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS 95
10.5 CONCLUSION 96
11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 97
11.1 OVERVIEW 98
11.2 DIAGNOSIS 101
11.2.1 IMAGING TESTS 101
11.2.1.1 CHEST X-RAY 102
11.2.1.2 CT SCAN 102
11.2.1.3 ULTRASOUND 102
11.2.1.4 OTHERS 102
11.2.2 BLOOD TEST 102
11.2.3 RESPIRATORY RATE 102
11.2.4 SPO2 TEST 102
11.2.5 OTHERS 103
11.3 TREATMENT 103
11.3.1 MECHANICAL VENTILATION 104
11.3.1.1 HIGH-FLOW NASAL O2 104
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 104
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 104
11.3.1.4 PRONE POSITIVE VENTILATION 104
11.3.1.5 OTHERS 104
11.3.2 CORTICOSTEROIDS 105
11.3.2.1 METHYLPREDNISOLONE 105
11.3.2.2 DEXAMETHASONE 105
11.3.2.3 OTHERS 105
11.3.3 ANTIVIRAL MEDICATION 106
11.3.3.1 REMDESIVIR 106
11.3.3.2 COMBINATION DRUGS 106
11.3.3.3 OTHERS 106
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 106
11.3.5 TOCILIZUMAB 106
11.3.6 OTHERS 106
12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 107
12.1 OVERVIEW 108
12.2 PARENTERAL 111
12.2.1 INTRAVENOUS 111
12.2.2 INTRAMUSCULAR 111
12.3 ORAL 112
12.4 OTHERS 112
13 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 113
13.1 OVERVIEW 114
13.2 CORONAVIRUS DISEASE 2019 (COVID-19) 117
13.3 SEPSIS 117
13.4 INHALATION OF HARMFUL SUBSTANCES 118
13.5 SEVERE PNEUMONIA 118
13.6 OTHERS 119
14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 120
14.1 OVERVIEW 121
14.2 HOSPITALS 124
14.3 SPECIALTY CLINICS 124
14.4 HOME HEALTHCARE 125
14.5 OTHERS 125
15 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 126
15.1 OVERVIEW 127
15.2 DIRECT TENDER 130
15.3 HOSPITAL PHARMACY 130
15.4 RETAIL PHARMACY 131
15.5 ONLINE PHARMACY 131

16 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION 132
16.1 EUROPE 133
16.1.1 GERMANY 143
16.1.2 FRANCE 147
16.1.3 U.K. 151
16.1.4 ITALY 155
16.1.5 SPAIN 159
16.1.6 TURKEY 163
16.1.7 HUNGARY 167
16.1.8 NETHERLANDS 171
16.1.9 SWITZERLAND 175
16.1.10 AUSTRIA 179
16.1.11 LITHUANIA 183
16.1.12 POLAND 187
16.1.13 RUSSIA 191
16.1.14 IRELAND 195
16.1.15 NORWAY 199
16.1.16 REST OF EUROPE 203
17 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 204
17.1 COMPANY SHARE ANALYSIS: EUROPE 204
18 SWOT ANALYSIS 205
19 COMPANY PROFILE 206
19.1 GILEAD SCIENCES INC. 206
19.1.1 COMPANY SNAPSHOT 206
19.1.2 REVENUS ANALYSIS 206
19.1.3 COMPANY SHARE ANALYSIS 207
19.1.4 PRODUCT PORTFOLIO 207
19.1.5 RECENT DEVELOPMENT 207
19.2 TERUMO CORPORATION 208
19.2.1 COMPANY SNAPSHOT 208
19.2.2 REVENUS ANALYSIS 208
19.2.3 COMPANY SHARE ANALYSIS 209
19.2.4 PRODUCT PORTFOLIO 209
19.2.5 RECENT DEVELOPMENT 209

19.3 GETINGE AB 210
19.3.1 COMPANY SNAPSHOT 210
19.3.2 REVENUS ANALYSIS 210
19.3.3 COMPANY SHARE ANALYSIS 211
19.3.4 PRODUCT PORTFOLIO 211
19.3.5 RECENT DEVELOPMENT 211
19.4 LIVANOVA PLC 212
19.4.1 COMPANY SNAPSHOT 212
19.4.2 REVENUE ANALYSIS 212
19.4.3 COMPANY SHARE ANALYSIS 213
19.4.4 PRODUCT PORTFOLIO 213
19.4.5 RECENT DEVELOPMENTS 213
19.5 MEDTRONIC 214
19.5.1 COMPANY SNAPSHOT 214
19.5.2 REVENUE ANALYSIS 214
19.5.3 COMPANY SHARE ANALYSIS 215
19.5.4 PRODUCT PORTFOLIO 215
19.5.5 RECENT DEVELOPMENTS 215
19.6 ALUNG TECHNOLOGIES, INC 216
19.6.1 COMPANY SNAPSHOT 216
19.6.2 PRODUCT PORTFOLIO 216
19.6.3 RECENT DEVELOPMENT 216
19.7 ARMSTRONG MEDICAL 217
19.7.1 COMPANY SNAPSHOT 217
19.7.2 PRODUCT PORTFOLIO 217
19.7.3 RECENT DEVELOPMENT 217
19.8 BESMED HEALTH BUSINESS CORP. 218
19.8.1 COMPANY SNAPSHOT 218
19.8.2 PRODUCT PORTFOLIO 218
19.8.3 RECENT DEVELOPMENTS 219
19.9 DRGERWERK AG & CO. KGAA 220
19.9.1 COMPANY SNAPSHOT 220
19.9.2 REVENUE ANALYSIS 220
19.9.3 PRODUCT PORTFOLIO 221
19.9.4 RECENT DEVELOPMENTS 221
19.10 EUROSETS 222
19.10.1 COMPANY SNAPSHOT 222
19.10.2 PRODUCT PORTFOLIO 222
19.10.3 RECENT DEVELOPMENT 222

19.11 F. HOFFMANN-LA ROCHE LTD 223
19.11.1 COMPANY SNAPSHOT 223
19.11.2 RECENT ANALYSIS 223
19.11.3 PRODUCT PORTFOLIO 224
19.11.4 RECENT DEVELOPMENTS 224
19.12 FISHER & PAYKEL HEALTHCARE LIMITED 225
19.12.1 COMPANY SNAPSHOT 225
19.12.2 REVENUE ANALYSIS 225
19.12.3 PRODUCT PORTFOLIO 226
19.12.4 RECENT DEVELOPMENTS 226
19.13 FRESENIUS SE & CO. KGAA 227
19.13.1 COMPANY SNAPSHOT 227
19.13.2 REVENUS ANALYSIS 227
19.13.3 PRODUCT PORTFOLIO 228
19.13.4 RECENT DEVELOPMENTS 228
19.14 HAMILTON MEDICAL 229
19.14.1 COMPANY SNAPSHOT 229
19.14.2 PRODUCT PORTFOLIO 229
19.14.3 RECENT DEVELOPMENT 229
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 230
19.15.1 COMPANY SNAPSHOT 230
19.15.2 PRODUCT PORTFOLIO 230
19.15.3 RECENT DEVELOPMENT 231
19.16 NIPRO 232
19.16.1 COMPANY SNAPSHOT 232
19.16.2 REVENUS ANALYSIS 232
19.16.3 PRODUCT PORTFOLIO 233
19.16.4 RECENT DEVELOPMENT 233
19.17 PFIZER INC. 234
19.17.1 COMPANY SNAPSHOT 234
19.17.2 REVENUS ANALYSIS 234
19.17.3 PRODUCT PORTFOLIO 235
19.17.4 RECENT DEVELOPMENT 235
19.18 RESMED 236
19.18.1 COMPANY SNAPSHOT 236
19.18.2 REVENUE ANALYSIS 236
19.18.3 PRODUCT PORTFOLIO 237
19.18.4 RECENT DEVELOPMENT 237

19.19 SMITHS MEDICAL 238
19.19.1 COMPANY SNAPSHOT 238
19.19.2 REVENUS ANALYSIS 238
19.19.3 PRODUCT PORTFOLIO 239
19.19.4 RECENT DEVELOPMENTS 239
19.20 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 240
19.20.1 COMPANY SNAPSHOT 240
19.20.2 PRODUCT PORTFOLIO 240
19.20.3 RECENT DEVELOPMENT 240
20 QUESTIONNAIRE 241
21 RELATED REPORTS 245